CO5700738A2 - Profarmaco de celecoxib - Google Patents

Profarmaco de celecoxib

Info

Publication number
CO5700738A2
CO5700738A2 CO05045079A CO05045079A CO5700738A2 CO 5700738 A2 CO5700738 A2 CO 5700738A2 CO 05045079 A CO05045079 A CO 05045079A CO 05045079 A CO05045079 A CO 05045079A CO 5700738 A2 CO5700738 A2 CO 5700738A2
Authority
CO
Colombia
Prior art keywords
composition
compound
water
celecoxib
therapeutically effective
Prior art date
Application number
CO05045079A
Other languages
English (en)
Inventor
Gary D Ewing
Matthew J Graneto
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of CO5700738A2 publication Critical patent/CO5700738A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members

Abstract

1.- Un compuesto que tiene la fórmula o una sal farmacéuticamente aceptable del mismo.2.- El compuesto de la reivindicación 1 que es la sal sódica de N-[[4-[5-(4-metilfenil)-3-(trifluorometil)-1H-pirazol-1-il]fenil]sulfonil]propanamida.3.- Una composición farmacéutica que comprende en una dosis unitaria de la misma una cantidad terapéuticamente eficaz en total de al menos un compuesto de las reivindicaciones 1 o 2, pudiendo administrarse la composición por vía oral y estando sustancialmente libre de agua y con medios para inhibir la degradación de dicho al menos un compuesto a celecoxib antes de la administración oral.4.- La composición de la reivindicación 3 en la que dicha cantidad terapéuticamente eficaz es una cantidad equivalente a de aproximadamente 10 mg a aproximadamente 1000 mg, preferiblemente de aproximadamente 50 mg a aproximadamente 400 mg de celecoxib.5.- La composición de la reivindicación 3 en la que el medio para inhibir la degradación comprende un medio para evitar sustancialmente la exposición de la composición al agua.6.- La composición de la reivindicación 5 en la que el medio para evitar la exposición comprende un envase o recipiente cerrado herméticamente y sustancialmente impermeable al agua.7.- La composición de la reivindicación 5 en la que el medio para evitar la exposición comprende un recubrimiento sustancialmente impermeable al agua.
CO05045079A 2002-11-12 2005-05-11 Profarmaco de celecoxib CO5700738A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42570302P 2002-11-12 2002-11-12

Publications (1)

Publication Number Publication Date
CO5700738A2 true CO5700738A2 (es) 2006-11-30

Family

ID=32313040

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05045079A CO5700738A2 (es) 2002-11-12 2005-05-11 Profarmaco de celecoxib

Country Status (17)

Country Link
US (1) US20040092566A1 (es)
EP (1) EP1562910A1 (es)
JP (1) JP2006508123A (es)
KR (1) KR20050072823A (es)
CN (1) CN1711247A (es)
AR (1) AR042037A1 (es)
AU (1) AU2003291278A1 (es)
BR (1) BR0316155A (es)
CA (1) CA2505635A1 (es)
CO (1) CO5700738A2 (es)
MX (1) MXPA05004991A (es)
NO (1) NO20052813L (es)
PL (1) PL376918A1 (es)
RU (1) RU2005114398A (es)
TW (1) TW200424179A (es)
WO (1) WO2004043934A1 (es)
ZA (1) ZA200503188B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003303591A1 (en) * 2002-12-30 2004-07-29 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
WO2006055381A2 (en) * 2004-11-16 2006-05-26 Merck & Co., Inc. Prodrugs of (2r)-2-propyloctanoic acid for treatment of stroke
CN101805290A (zh) * 2010-04-01 2010-08-18 中国人民解放军第四军医大学 氨基磺酰吡唑类化合物及其用途
BRPI1003050B1 (pt) * 2010-08-04 2021-05-25 Universidade Federal De Minas Gerais Compostos derivados do ácido araquidônico substituídos com análogos de coxibes para tratamento de dor
KR101245078B1 (ko) * 2010-11-11 2013-03-18 부산대학교 산학협력단 대장 선택성 셀레콕시브 전구체 화합물 및 이를 유효성분으로 함유하는 대장성 질환 치료 또는 예방용 약학조성물
US9562015B2 (en) 2011-11-17 2017-02-07 The Regents Of The University Of Colorado, A Body Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations
CN104892514A (zh) * 2015-05-19 2015-09-09 广州诺威生物技术有限公司 一种咪唑类新化合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69719496T2 (de) * 1996-04-12 2004-04-08 G.D. Searle & Co., Chicago N-[[4-(5-METHYL-3-PHENYLISOXAZOL-4-YL]PHENYL]SULPHONYLPROPYLAMID und sein NATRIUMSALZ ALS PRO-PHARMAKON VON COX-2 INHIBITOREN

Also Published As

Publication number Publication date
RU2005114398A (ru) 2006-01-20
AU2003291278A1 (en) 2004-06-03
TW200424179A (en) 2004-11-16
PL376918A1 (pl) 2006-01-09
WO2004043934A1 (en) 2004-05-27
MXPA05004991A (es) 2005-08-02
NO20052813L (no) 2005-08-02
CA2505635A1 (en) 2004-05-27
AR042037A1 (es) 2005-06-08
KR20050072823A (ko) 2005-07-12
BR0316155A (pt) 2005-09-27
NO20052813D0 (no) 2005-06-10
ZA200503188B (en) 2006-11-29
JP2006508123A (ja) 2006-03-09
CN1711247A (zh) 2005-12-21
US20040092566A1 (en) 2004-05-13
EP1562910A1 (en) 2005-08-17

Similar Documents

Publication Publication Date Title
CO5700738A2 (es) Profarmaco de celecoxib
ES2546847T3 (es) Formulaciones de un inhibidor de la Src/Abl
AR037255A1 (es) Composiciones farmaceuticas que contienen oxibutinina
IT1271495B (it) Composizione farmaceutica contenente 3-2 (dimetilammino) etil-n-metil-1h-indol-5-metansolfonammide, relativo procedimento di preparazione e impiego della stessa nel trattamento di mammiferi
ES2545076T3 (es) Uso del inhibidor de HDAC panobinostat para el tratamiento de mieloma
JP2008521827A5 (es)
ES2530719T3 (es) Formulaciones de oxicodona para ser administradas una vez al día
CO5611172A2 (es) Stents recubiertos con n-{5-[4-(4-metil-piperazino-metil) -benozilamido]-2-metilfenil}-4-(3-piridil)-2-pirimidin-amina
ES2255287T3 (es) Composiciones para el tratamiento de la leucemia linfocitica cronica.
ECSP066950A (es) Combinaciones de glicopirrolato y agonistas del adrenoceptor-beta2
CU23468B7 (es) Forma de dosificación de pramipexol en una dosis única diaria
PE20030347A1 (es) Composiciones farmaceuticas, kits y procedimientos que comprenden combinaciones de agonistas/antagonistas de estrogenos, estrogenos y progestinas
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
AR018862A1 (es) Formulacion farmaceutica de liberacion prolongada, mejorada para la administracion oral de nefazodona o una sal farmaceuticamente aceptable de la misma;forma de dosificacion oral que la comprende y uso de dicha formulacion para preparar dicha forma de dosificacion
RU2006101458A (ru) 2-аминобензотиазолы в качестве обратных агонистов рецепторов cb1
BG102669A (bg) Метод за лечение и фармацевтичен състав
RS54050B1 (en) FORMULATIONS AND METHODS FOR THE TREATMENT OF AMYLOIDOSIS
JP2004509857A5 (es)
SE9901573D0 (sv) New compounds
KR930009605A (ko) 소염 또는 진통제
PE20221455A1 (es) Composicion farmaceutica que comprende selexipag
CO5580741A2 (es) Composicion farmaceutica que comprende un agonista de receptor de 5ht1
CO5011084A1 (es) Composiciones y metodos para tratar trastornos respiratorios
CO5580744A2 (es) Forma de dosificacion oral de un profarmaco de sulfonamida
PE20020351A1 (es) Composiciones farmaceuticas que comprenden acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico como inhibidor de la ciclooxigenasa-2

Legal Events

Date Code Title Description
FC Application refused